Compare SAMG & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | SLGL |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 117.8M |
| IPO Year | 2013 | 2018 |
| Metric | SAMG | SLGL |
|---|---|---|
| Price | $15.75 | $61.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 39.6K | 22.1K |
| Earning Date | 03-05-2026 | 11-20-2025 |
| Dividend Yield | ★ 5.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $125,322,000.00 | $18,970,000.00 |
| Revenue This Year | $3.44 | $122.71 |
| Revenue Next Year | $9.39 | N/A |
| P/E Ratio | $21.54 | ★ N/A |
| Revenue Growth | 4.23 | ★ 62.04 |
| 52 Week Low | $13.23 | $4.02 |
| 52 Week High | $19.04 | $74.25 |
| Indicator | SAMG | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 64.28 |
| Support Level | $15.26 | $60.20 |
| Resistance Level | $16.16 | $71.99 |
| Average True Range (ATR) | 0.38 | 5.56 |
| MACD | -0.02 | 1.48 |
| Stochastic Oscillator | 61.12 | 64.61 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.